|
Name |
Verruculogen
|
Molecular Formula | C27H33N3O7 | |
IUPAC Name* |
(9R,14S,17S,23R,24S)-23,24-dihydroxy-5-methoxy-12,12-dimethyl-9-(2-methylprop-1-enyl)-10,11-dioxa-8,15,21-triazahexacyclo[12.10.1.02,7.08,25.015,23.017,21]pentacosa-1(25),2(7),3,5-tetraene-16,22-dione
|
|
SMILES |
CC(=C[C@@H]1N2C3=C(C=CC(=C3)OC)C4=C2[C@H](CC(OO1)(C)C)N5C(=O)[C@@H]6CCCN6C(=O)[C@@]5([C@H]4O)O)C
|
|
InChI |
InChI=1S/C27H33N3O7/c1-14(2)11-20-29-18-12-15(35-5)8-9-16(18)21-22(29)19(13-26(3,4)37-36-20)30-24(32)17-7-6-10-28(17)25(33)27(30,34)23(21)31/h8-9,11-12,17,19-20,23,31,34H,6-7,10,13H2,1-5H3/t17-,19-,20+,23-,27+/m0/s1
|
|
InChIKey |
LRXYHMMJJCTUMY-GWXUGYLUSA-N
|
|
Synonyms |
verruculogen; 12771-72-1; TR 1 toxin; TR 1; CHEBI:72765; (5R,10S,10aR,14aS,15bS)-10,10a-dihydroxy-6-methoxy-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)-1,10,10a,14,14a,15b-hexahydro-12H-3,4-dioxa-5a,11a,15a-triazacycloocta[1,2,3-lm]indeno[5,6-b]fluorene-11,15(2H,13H)-dione; (9R,14S,17S,23R,24S)-23,24-dihydroxy-5-methoxy-12,12-dimethyl-9-(2-methylprop-1-enyl)-10,11-dioxa-8,15,21-triazahexacyclo[12.10.1.02,7.08,25.015,23.017,21]pentacosa-1(25),2(7),3,5-tetraene-16,22-dione; 4-Methyl-4-(2-(4-nitro-N-phenylbenzamido)ethyl)morpholin-4-ium bromide; Verrculogen; Verruculogen, powder; CHEMBL551369; DTXSID30894030; TR1; MFCD00079645; ZINC85564414; AKOS030213151; 5H,12H-3,4-Dioxa-5a,11a,15a-triazacyclooct[lm]indeno[5,6-b]fluorene-11,15(2H,13H)-dione,1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-, (5R,10S,10aR,14aS,15bS)-; C20045; J-005532; (5R,10S,10aR,14aS,15bS)-10,10a-Dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)-1,10,10a,12,13,14,14a,15b-octahydro-3,4-dioxa-5a,11a,15a-triazacycloocta[lm]indeno[5,6-b]fluorene-11,15(2H,5H)-dione; (5R-(5alpha,10 alpha,10aalpha,14aalpha,15balpha))-1,10,10a,14,14a,15b-Hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-5H,12H-3,4-dioxa-5a,11a,15a-triaza cyclooct (1m) indeno (5,6-b)fluorene-11,15(2H,13H)-dione; 10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)- 1,10,10a,14,14a,15b-hexahydro-5H,12H-3,4-dioxa-5a,11a,15a- triazacyclooct[lm]indeno[5,6-b]fluorene-11,15(2H,13H)-dione; 5H,12H-3,4-Dioxa-5a,11a,15a-triazacyclooct(lm)indeno(5,6-b)fluorene-11,15(2H,13H)-dione, 1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-, (5R,10S,10aR,14aS,15bS)-; 5H,12H-3,4-Dioxa-5a,11a,15a-triazacyclooct(lm)indeno(5,6-b)fluorene-11,15(2H,13H)-dione, 1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-,(5R-(5-alpha,10-alpha,10a-alpha,14a-alpha-15b-alpha))-; 8H5
|
|
CAS | 12771-72-1 | |
PubChem CID | 13887805 | |
ChEMBL ID | CHEMBL551369 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 511.6 | ALogp: | 1.8 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 114.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 37 | QED Weighted: | 0.467 |
Caco-2 Permeability: | -4.874 | MDCK Permeability: | 0.00001460 |
Pgp-inhibitor: | 0.995 | Pgp-substrate: | 0.534 |
Human Intestinal Absorption (HIA): | 0.063 | 20% Bioavailability (F20%): | 0.47 |
30% Bioavailability (F30%): | 0.904 |
Blood-Brain-Barrier Penetration (BBB): | 0.255 | Plasma Protein Binding (PPB): | 83.16% |
Volume Distribution (VD): | 1.43 | Fu: | 9.42% |
CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.117 |
CYP2C19-inhibitor: | 0.548 | CYP2C19-substrate: | 0.912 |
CYP2C9-inhibitor: | 0.689 | CYP2C9-substrate: | 0.796 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.15 |
CYP3A4-inhibitor: | 0.472 | CYP3A4-substrate: | 0.936 |
Clearance (CL): | 8.571 | Half-life (T1/2): | 0.271 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.989 |
Drug-inuced Liver Injury (DILI): | 0.989 | AMES Toxicity: | 0.039 |
Rat Oral Acute Toxicity: | 0.082 | Maximum Recommended Daily Dose: | 0.997 |
Skin Sensitization: | 0.192 | Carcinogencity: | 0.459 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.802 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000842 | 0.787 | D06YFA | 0.277 | ||||
ENC000837 | 0.636 | D02IQY | 0.263 | ||||
ENC001958 | 0.595 | D01TSI | 0.257 | ||||
ENC003264 | 0.595 | D0V3ZA | 0.250 | ||||
ENC003265 | 0.528 | D0SP3D | 0.250 | ||||
ENC005479 | 0.508 | D09NNH | 0.243 | ||||
ENC003281 | 0.500 | D06HBQ | 0.242 | ||||
ENC003013 | 0.496 | D01XWG | 0.235 | ||||
ENC002064 | 0.475 | D0Q0PR | 0.235 | ||||
ENC002846 | 0.450 | D0V6OA | 0.232 |